Therapeutic approaches to the treatment of Alzheimer's disease

Drugs of Today

Volumn 38, Issue 9, 2002, Pages 631-637

  Yamada, Kiyofumi ^a   Toshitaka, Nabeshima ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BETA SECRETASE; CHELATING AGENT; CHOLINESTERASE INHIBITOR; CLIOQUINOL; CORTICOSTEROID; DONEPEZIL; ENZYME INHIBITOR; GALANTAMINE; GAMMA SECRETASE; GLYCOGEN SYNTHASE KINASE 3BETA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METAL CHELATE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; RIVASTIGMINE; SIMVASTATIN; TACRINE; TAU PROTEIN;

ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITION; DISEASE COURSE; ESTROGEN THERAPY; HUMAN; IMMUNIZATION; NEUROFIBRILLARY TANGLE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN PHOSPHORYLATION; REVIEW; SENILE PLAQUE; SIDE EFFECT; SUBACUTE MYELOOPTIC NEUROPATHY;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ASPARTIC ENDOPEPTIDASES; CHELATING AGENTS; CHOLINESTERASE INHIBITORS; ENDOPEPTIDASES; ENZYME INHIBITORS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PALLIATIVE CARE;

EID: 0036750190     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2002.38.9.696538     Document Type: Review

References (47)

1. Selkoe, D.J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 1999, 399: A23-31.
2. Coyle, J.T., Price, D.L., DeLong, M.R. Alzheimer's disease: A disorder of central cholinergic innervation. Science 1983, 219: 1184-90.
3. Ballard, C.G. Advances in the treatment of Alzheimer's disease: Benefits of dual cholinesterase inhibition. Eur Neurol 2002, 47: 64-70.
4. Bullock, R. New drugs for Alzheimer's disease and other dementias. Br J Pschiat 2002, 180: 135-9.
5. Gauthier, S. Advances in the pharmacotherapy of Alzheimer's disease. CAMJ 2002, 166: 616-23.
6. Nabeshima, T., Yamada, K. Development of anti-demential drugs for Alzheimer's disease: Present and future. In: Advances in Behavioral Biology, Vol. 51. Mapping the Progress of Alzheimer's and Parkinson's Disease. Y. Mizuno, A. Fisher and I. Hanin (Eds.). Kluwer Academic/Plenum Publishers: New York 2002, 223-8.
7. McGeer, P.L., Rogers, J. Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology 1992, 42: 447-9.
8. Rogers, J., Kirby, L.C., Hempelman, S.R. et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993, 43: 1609-11.
9. in t'Veld, B.A., Ruitenberg, A., Hofman, A. et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Eng J Med 2001, 345: 1515-21.
10. Wolson, C., Perrault, A., Moride, Y., Esdaile, J.M., Abenhaim, L., Momoli, F. A case-control analysis of nonsteroidal anti-inflammatory drugs and Alzheimer's disease: Are they protective? Neuroepidemiology 2002, 21: 81-6.
11. Simpkins, J.W., Green, P., Gridley, K.E., Singh, M., de Fiebre, N.C., Rajakumar, G. Role of estrogen replacement therapy in memory enhancement and prevention of neuronal loss associated with Alzheimer's disease. Am J Med 1997, 103 (3A): 19-25S.
12. Yamada, K., Tanaka, T, Han, D., Senzaki, K., Kameyama, T., Nabeshima, T. Protective effects of idebenone and α-tocopherol on β-amyloid-(1-42) induced learning and memory deficits in rats: Implications of oxidative stress in β-amyloid-induced neurotoxicity in vivo. Eur J Neurosci 1999, 11: 83-90.
13. Yamada, K., Nabeshima, T. Animal models of Alzheimer's disease and evaluation of anti-dementia drugs. Pharmacol Ther 2000, 88: 93-113.
14. Pratico, D., Uryu, K., Leight, S., Trojanoswki, J.Q., Lee, V.M.-Y. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 2001, 21: 4183-7.
15. Sano, M., Ernesto, C., Thomas, R.G. et al. A controlled trial of selegiline, α-tocopherol, or both as treatment for Alzheimer's disease. New Eng J Med 1997, 336: 1216-22.
16. Tran, M.H., Yamada, K., Olariu, A., Mizuno, M., Ren, X.H., Nabeshima, T. Amyloid β-peptide induces nitric oxide production in rat hippocampus: Association with cholinergic dysfunction and amelioration by inducible nitric oxide synthase inhibitors. FASEB J 2001, 15: 1407-9.
17. Tran, M.H., Yamada, K., Nabeshima, T. Amyloid β-peptide induces cholinergic dysfunction and cognitive deficits. Peptides 2002, in press.
18. Hardy, H. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 1997, 20: 154-9.
19. Hussain, I., Powell, D., Howlett, D.R. et al. Identification of a novel aspartic protease (Asp 2) as β-secretase. Mol Cell Neurosci 1999, 14: 419-27.
20. Sinha, S., Anderson, J.P., Barbour, R. et al. Purification and cloning of amyloid precursor protein β-secretase from human brain. Nature 1999, 402: 537-40.
21. Vassar, R., Bennett, B.D., Babu-Khan, S. et al. β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286: 735-41.
22. Yan, R., Bienkowski, M.J., Shuck, M.E. et al. Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity. Nature 1999, 402: 533-7.
23. Wolf, M.S., Xia, W., Ostaszewski, B.L., Diehl, T.S., Kimberly, W.T., Selkoe, D.J. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity. Nature 1999, 398: 513-7.
24. Li, Y.-M., Xu, M., Lai, M.-T. et al. Photoactivated β-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 2000, 405: 689-94.
25. Esler, W.P., Kimberly, W.T., Ostaszewski, B.L. et al. Transition-state analogue inhibitors of γ-secretase bind directly to presenilin-1. Nat Cell Biol 2000, 2: 428-34.
26. Dovey, H.F., John, V., Anderson, J.P. et al. Functional γ-secretase inhibitors reduce β-amyloid peptide levels in brain. J Neurochem 2001, 76: 173-81.
27. De Strooper, B., Annaert, W., Cupers, P. et al. A presenilin-1-dependent β-secretase-like protease mediates release of Notch intracellular domain. Nature 1999, 398: 518-22.
28. Schenk, D., Barbour, R., Dunn, W. et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400: 173-7.
29. Janus, C., Pearson, J., McLaurin, J. et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000, 408: 979-82.
30. Morgan, D., Diamond, D.M., Gottschall, P.E. et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408: 982-5.
31. Brad, F., Cannon, C., Barbour, R. et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000, 6: 916-9.
32. Birminghan, K., Frantz, S. Set back to Alzheimer vaccine studies. Nat Med 2002, 8: 199-200.
33. Münch, G., Robinson, S.R. Alzheimer's vaccine: A cure as dangerous as the disease? J Neural Transm 2002, 109: 537-9.
34. Bush, A.I., Pettingell, W.H., Multhaup, G. et al. Rapid induction of Alzheimer Aβ amyloid formation by zinc. Science 1994, 265: 1464-7.
35. Huang, X., Cuajungco, M.P., Atwood, C.S. et al. Cu(II) potentiation of Aβ neurotoxicity: Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem 1999, 274: 37111-6.
36. Atwood, C.S., Scarpa, R.C., Huang, X. et al. Characterization of copper interactions with Alzhemier Aβ peptides - Identification of an attomolar affinity copper binding site on Aβ1-42. J Neurochem 2000, 75: 1219-33.
37. Lovell, M.A., Robertson, J.D., Teesdale, W.J., Campbell, J.L., Markesbery, W.R. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 1998, 158: 47-52.
38. Cherny, R.A., Legg J.T., McLean, C.A. et al. Aqueous dissolution of Alzheimer's disease Aβ amyloid deposits by biometal depletion. J Biol Chem 1999, 274: 23223-8.
39. Yassin, M.S., Ekblom, J., Xilinas, M., Gottfries, C.G., Oreland, L. Changes in uptake of vitamin B(12) and trace metals in brains of mice treated with clioquinol. J Neurol Sci 2000, 173: 40-4.
40. Cherny, R.A., Atwood, C.S., Xilinas, M.E. et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001, 30: 665-76.
41. Corder, E.H., Saunders, A.M., Strittmatter, W.J. et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261: 921-3.
42. Wolzin, B., Kellman, W., Ruosseau, P., Celesia, G.G., Siegel, G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000, 57: 1439-43.
43. Jick, H., Zornberg, G.L., Jick, S.S., Seshadri, S., Drachman, D.A. Statins and the risk of dementia. Lancet 2000, 356: 1627-37.
44. Fassbender, K., Simons, M., Bergmann, C. et al. Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo. Proc Natl Acad Sci U S A 2001, 98: 5856-61.
45. Busciglio, J., Lorenzo, A., Yeh, J., Yankner, B.A. β-Amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 1995, 14: 879-88.
46. Takashima, A., Noguchi, K., Sato, K., Hoshino, T., Imahori, K. Tau protein kinase I is essential for amyloid β-protein-induced neurotoxicity. Proc Natl Acad Sci U S A 1993, 90: 7789-93.
47. Martinez, A., Alonso, M., Castro, A., Perez, C., Moreno F.J. First non-ATP competitive glycogen synthase kinase 3β (GSK-3β) inhibitors: Thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem 2002, 45: 1292-9.